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ABSTRACT The positively charged protein transduction domain of the HIV-1 TAT protein (TAT-PTD; residues 47–57 of TAT)
rapidly translocates across the plasma membrane of living cells. This property is exploited for the delivery of proteins, drugs,
and genes into cells. The mechanism of this translocation is, however, not yet understood. Recent theories for translocation
suggest binding of the protein transduction domain (PTD) to extracellular glycosaminoglycans as a possible mechanism. We
have studied the binding equilibrium between TAT-PTD and three different glycosaminoglycans with high sensitivity isothermal
titration calorimetry and provide the ﬁrst quantitative thermodynamic description. The polysulfonated macromolecules were
found to exhibit multiple identical binding sites for TAT-PTD with only small differences between the three species as far as the
thermodynamic parameters are concerned. Heparan sulfate (HS, molecular weight, 14.2 6 2 kDa) has 6.3 6 1.0 independent
binding sites for TAT-PTD which are characterized by a binding constant K0 ¼ (6.0 6 0.6) 3 105 M1 and a reaction enthalpy
DH0pep ¼ 4:6 6 1:0 kcal/mol at 288C. The binding afﬁnity, DG0pep, is determined to equal extent by enthalpic and entropic
contributions. The HS-TAT-PTD complex formation entails a positive heat capacity change of DC0p ¼ 1135 cal/mol peptide,
which is characteristic of a charge neutralization reaction. This is in contrast to hydrophobic binding reactions which display
a large negative heat capacity change. The stoichiometry of 6–7 TAT-PTD molecules per HS corresponds to an electric charge
neutralization. Light scattering data demonstrate a maximum scattering intensity at this stoichiometric ratio, the intensity of
which depends on the order of mixing of the two components. The data suggest cross-linking and/or aggregation of HS-TAT-
PTD complexes. Two other glycosaminoglycans, namely heparin and chondroitin sulfate B, were also studied with isothermal
titration calorimetry. The thermodynamic parameters are K0 ¼ (6.0 6 0.8) 3 105 M1 and DH0pep ¼ 5:1 6 0:7 kcal/
mol for heparin and K0 ¼ (2.5 6 0.5) 3 105 M1 and DH0pep ¼ 3:2 6 0:4 kcal/mol for chondroitin sulfate B at 288C. The close
thermodynamic similarity of the three binding molecules also implies a close structural relationship. The ubiquitous occurrence
of glycosaminoglycans on the cell surface together with their tight and rapid interaction with the TAT protein transduction
domain makes complex formation a strong candidate as the primary step of protein translocation.
INTRODUCTION
The human immunodeﬁciency virus type 1 (HIV-1) encodes
15 distinct proteins (for a review see Frankel and Young,
1998). One of them is the trans-acting activator of
transcription (TAT) (Sodroski et al., 1985), a protein of
101 (in human blood) or 86 amino acids, depending on the
cleavage of the C-terminus observed in some laboratory HIV
strains (Rana and Jeang, 1999). The main function of this
protein is to potentiate the transcription of the viral DNA
insert (a proviral genome of ;9200 nucleic acid basepairs
inserted into the host cell’s DNA) (Clavel et al., 1986;
Howard and Rasheed, 1996; Roy et al., 1989; Salminen et al.,
1995) into mRNA carried out by the host cell RNA
polymerase. Without TAT, the host cell polymerase complex
stops the elongation of the viral RNA soon after ;100
nucleotides (Laspia et al., 1989). From a physical-chemical
point of view, the TAT protein can be divided into six
regions—namely the acidic (residues 2–11) and cysteine-
rich regions (residues 22–37), the hydrophobic core (resi-
dues 38–48), the basic (residues 49–57) and the glutamine-
rich regions (residues 58–72), and the RGD motif (residues
72–86) (Bayer et al., 1995; Churcher et al., 1993; Orsini
et al., 1996). Essential for binding to the negatively charged
mRNA is the basic region of TAT (Long and Crothers, 1995;
Luo et al., 1993; Weeks et al., 1990), and this binding
becomes speciﬁc for TAT activation region (TAR) when the
hydrophobic core is ﬂanking the basic region (Churcher et al.,
1993). (The trans-acting TAT binds to a structure designated
as TAR, which is a 59-base mRNA hairpin located at the 59
end of the initial HIV RNA transcript, i.e., located close to
the point at which the RNA transcription begins, but far
away, i.e., trans, from the location of the TAT gene, at
nucleotides 5365–5607. The binding of TAT to TAR
induces a structural change of the TAR. This structural
change enables binding of host cell kinases that phosphor-
ylate the RNA polymerase II enzyme complex which, in
turn, promotes prolongation of the transcription; see Rana
and Jeang, 1999.) The cystein-rich region of TAT, in turn, is
important for activation of a complex containing kinases, an
elongation factor, and a polymerase, an activation which
occurs even without other regions of TAT. When handling
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larger amounts of TAT it should be realized that TAT
(residues 31–61) produced neurotoxicity in a dose-de-
pendent manner (Mabrouk et al., 1991; Nath et al., 1996).
Small fragments of TAT, comprising the basic region of
TAT, have been found to traverse biological membranes in
vivo very efﬁciently within 5 to 10 min (Frankel and Pabo,
1988; Green and Loewenstein, 1988) by a still unknown
mechanism. They may cargo at the same time covalently
bound proteins through the membrane (Fawell et al., 1994),
a process which has been termed protein transduction (PT)
(Gius et al., 1997). Related peptides of similar structure
(arginine- and lysine-rich) and similar protein transduction
properties were found inDrosophila (AntP¼ penetratin) and
herpesvirus (vp22), or were created synthetically (trans-
portan). These peptides are also called cell-penetrating
peptides (CPP) (Lindgren et al., 2000). CPPs may transport
large proteins through biological membranes such as en-
zymes of molecular size up to 120 kDa (Schwarze et al.,
1999), antibodies (Stein et al., 1999), DNA phages (Eguchi
et al., 2001), 200-nm liposomes (Torchilin et al., 2001), and
40-nm iron beads (Lewin et al., 2000), provided these
entities are covalently attached to theCPPs. This rapid and ap-
parently cell-strain-independent (Mann and Frankel, 1991)
transduction makes the CPPs especially interesting for intra-
cellular drug delivery (Wadia and Dowdy, 2002; Wender
et al., 2000) and rapid nonviral gene transfer (Eguchi et al.,
2001).
For the TAT protein it has been found that the minimal
amino acid sequence required for membrane translocation
comprises residues 47–57 (H3N
1-YGRKKRRQRRR-COO;
Fig.1 A) (Ho et al., 2001; Vives et al., 1997), denoted TAT
protein transduction domain (TAT-PTD) in the following.
The physical mechanism of how TAT, TAT-PTD, and re-
lated peptides translocate across the membrane is currently
unknown. It has been observed that a d-amino acid sub-
stituted enantiomer of TAT crosses the membrane with
similar efﬁciency as the natural l-enantiomer so that a speciﬁc
receptor for TAT was excluded (Derossi et al., 1996). The
translocation was not impaired when cells were treated with
extracellular proteases and, furthermore, the TAT peptide
could not be cross-linked to membrane proteins (Mann and
Frankel, 1991). The translocation was not abolished at 48C
where cellular energy production should be signiﬁcantly
reduced (Derossi et al., 1996; Pooga et al., 1998); however,
inhibition of the oxidative phosphorylation with sodium
azide inhibited the translocation of CPPs (Mitchell et al.,
2000). The transduction could be reproduced in many
eukaryotic cells (Mann and Frankel, 1991), but the degree of
internalization was cell-type-dependent (Mai et al., 2002;
Violini et al., 2002) and was not found in yeast (Schwarze
et al., 2000). The involvement of endocytosis is controver-
sial. Whereas two studies exclude a classical endocytosis
(Mitchell et al., 2000; Vives et al., 1997), two other studies
suggest an adsorptive-mediated endocytosis as a possible
mechanism (Huang et al., 1995; Mann and Frankel, 1991).
From a physical point of view it is unlikely that a short,
highly charged peptide such as TAT-PTD (zp ¼ 18 at
physiological pH) can cross the hydrophobic lipid bilayer of
a cell membrane simply by passive diffusion. Since an active
uptake appears to be excluded by the in vivo studies (Derossi
et al., 1996), complex formation between the cationic peptide
and an anionic binding partner has been proposed as an
alternative mechanism to reduce the effective electric charge
of the peptide. Recent theories suggest either glycosamino-
glycans such as heparan sulfate (Frankel and Pabo, 1988;
Sandgren et al., 2002; Tyagi et al., 2001) or lipids (Derossi
et al., 1996; Prochiantz, 2000) of the cell membrane as
potential complexation agents.
In this study we have therefore characterized the thermo-
dynamic equilibrium between TAT-PTD and three different
glycosaminoglycans, i.e., heparan sulfate, heparin, and chon-
droitin sulfate B. Using high-sensitivity isothermal titration
calorimetry (ITC) and static light scattering we investigate
the thermodynamic details of the binding mechanism and
report on the binding constant K0, the reaction enthalpy,
DH0, and the number of binding sites.
MATERIALS AND METHODS
Materials
N-a-Fmoc-protected amino acids and OH-functionalized acid-labile TGA
resin were purchased from Novabiochem (Laufelﬁngen, Switzerland).
Heparan sulfate, fraction I, sodium salt (average molecular weight,
14,200; sulfate content 6.44%), was from Celsus Laboratories (Cincinnati,
OH); chondroitin sulfate B, sodium salt, (from bovine mucosa, average
molecular weight, 28,000; sulfate content 5.6%) was from Bio Chemika
(Buchs, Switzerland). Low molecular heparin (sodium salt, porcine
intestinal mucosa, average molecular weight, 6000; sulfate content 10.2%)
and all other chemicals (analytical grade) were from Fluka (Buchs,
Switzerland).
FIGURE 1 Chemical structure of the compounds investigated. (A) TAT-
PTD: 11-amino acid PTD of HIV-1 TAT (residues 47–57); most abundant
(;70%) disaccharide unit of (B) heparan sulfate/heparin; and (C)
chondroitin sulfate B.
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Synthesis and puriﬁcation of TAT-PTD
The peptide employed in this study is shown in Fig. 1. It represents amino
acids 47–57 of the human immunodeﬁciency virus type I (HIV-1) TAT
protein. The peptide contains six Arg and two Lys residues and is thus highly
charged (net charge zp ¼ 18 at physiological pH). Solid phase peptide
synthesis of the 11-amino acid TAT-PTD (H3N
1-YGRKKRRQRRR-
COO, molecular weight, 1560.81) was performed on an Abimed
EPS221 peptide synthesizer (Langenfeld, Germany) using Fmoc-protected
amino acids. After synthesis, the peptide was puriﬁed by preparative high
pressure liquid chromatography on a reverse phase column Lichrosorb RP-
18/250-25 (Merck, Darmstadt, Germany) using a ﬂow rate of 15 mL/min at
70 bar and a linear elution gradient from 5 to 10% acetonitrile within 1 h.
The mass of the peptide was conﬁrmed by electrospray ionization mass
spectrometry (Finnigan TSQ7000; San Jose, CA). Peptide purity ([98%)
was measured by analytical high pressure liquid chromatography. After
puriﬁcation, the peptide was suspended in water, neutralized to pH 7.40, and
lyophilized. The effective peptide concentration was measured as amino acid
content after acid hydrolysis.
Buffer
Solutions were prepared with buffer containing 100 mM NaCl and 10 mM
TRIS at pH 7.4. The samples were ﬁltered (0.44 mm) and degassed
immediately before use (140 mbar, 8 min).
Isothermal titration calorimetry
The heat ﬂow resulting from the binding of the TAT-PTD peptide to heparan
sulfate and related compounds was measured with high-sensitivity iso-
thermal titration calorimetry using a Microcal VP-ITC calorimeter (Micro-
cal, Northampton, MA) with a reaction cell volume of Vcell ¼ 1.4037 mL.
Two types of titrations were performed. In the ﬁrst, the calorimeter cell
contained the glycosaminoglycan solution (e.g., heparan sulfate) at a low
concentration (C0HS; 12 mM) which was titrated with Vinj ¼ 10 mL aliquots
of a concentrated TAT-PTD solution (C0p; 800 mM). Each injection
increased the total peptide concentration in the calorimeter cell stepwise by
dc ¼ 5.7 mM. At the same time the reaction volume was also increased and
a correction factor was applied for both reactant concentrations. The heparan
sulfate concentration after ni injections is Ci;HS ¼ C0HS Vcell= ðVcell1 ni VinjÞ:
Accordingly, the peptide concentration in the calorimeter cell is
Ci;p ¼ C0p ni Vinj=ðVcell1 ni VinjÞ: The heparan sulfate employed in this
study has a molecular weight of 14.2 6 2 kDa and contains ;30 sulfated
disaccharides units. For the initial steps of the injection, the heparan sulfate
(measured in sulfate residues) is much in excess over the added peptide.
In the second type of experiment, the order of solutions was inverted. The
calorimeter cell now contained the TAT-PTD peptide at low concentrations
(C0p; 27 80 mM). The concentration of the injected glycosaminoglycan
solutions varied between 140 and 500 mM for heparan sulfate, 100–200 mM
for chondroitin sulfate B, and 0.8–1.2 mM for heparin. The injection volume
in these titrations was Vinj ¼ 2–10 mL. In the initial phase of these titrations
the peptide was much in excess over the added glycosaminoglycan.
For each type of titration, the corresponding control titrations were also
performed, i.e., the TAT-PTD solution or the glycosaminoglycan solution
were injected into pure buffer. The corresponding heats of dilution were
subtracted from the heats measured for the binding reaction. For the
glycosaminoglycans the heat of dilution were small (from 1 to 11 mcal),
for the concentrated TAT-PTD solutions the heat of dilution were constant at
from 10 to 20 mcal. All solutions were degassed immediately before use
(140 mbar, 8 min).
Static right-angle light scattering
Quartz cuvettes with a cell length of 1 cm and a volume of 3.5 mL were used
for light-scattering experiments. The cells were ﬁlled with 2.8 mL of peptide
(heparan sulfate) solution and 4 mL aliquots of a heparan sulfate (peptide)
solution were added in 1-min intervals. Static light scattering at right-angle
was measured with a Jasco FP 777 ﬂuorimeter (Tokyo, Japan) at a
wavelength of 350 nm under constant stirring and at a temperature of 288C.
As a control, heparan sulfate (peptide) was injected into buffer without
peptide (heparan sulfate).
Circular dichroism
Circular dichroism spectra were recorded between 240 and 190 nm using
a quartz cuvette of 0.2-mm length and 180-mL volume, a scanning speed of
50 nm/min, and a response time of 0.5 s. Fifty scans were averaged using
a Jasco J720 spectropolarimeter at 288C. All spectra were corrected by
subtracting the buffer baseline. The TAT-PTD concentration was 60 mM for
variable concentrations of heparan sulfate.
RESULTS
Interaction of TAT-PTD with heparan sulfate
measured with isothermal titration calorimetry
Peptide-into-HS titration
Fig. 2 shows the titration of a heparan sulfate (HS) solution
(C0HS ¼ 12 mM) with a concentrated TAT-PTD solution
(C0p ¼ 791 mM). The calorimeter cell (Vcell ¼ 1.4037 mL)
contained the heparan sulfate and the TAT-PTD solution was
injected in 10 mL aliquots every 10 min. The heat ﬂow as
a function of time is shown in Fig. 2 A. Integration of the
titration peaks yields the heats of reaction, hi (Fig. 2 B).
These are initially constant with hi55 mcal and then drop
sharply to a residual hi  11.5 mcal. As a control, the same
TAT-PTD solution was injected into pure buffer. The heat of
FIGURE 2 Isothermal titration calorimetry. Titration of TAT-PTD into
heparan sulfate. (A) Heat ﬂow. The heparan sulfate concentration in the
reaction cell (Vcell ¼ 1.4037 mL) is 12 mM. The peptide concentration in the
injection syringe is 791 mM. Each titration peak corresponds to the injection
of 10 mL every 10 min. Buffer for both solutions is 10 mM Tris and 100 mM
NaCl at pH 7.4. Temperature is 288C. (B) Heats of reaction hi (integration of
the heat ﬂow peaks of A) as a function of the molar ratio of TAT-PTD/
heparan sulfate. Unﬁlled diamonds represent experimental data. The solid
line is a least-square ﬁt using the binding model described by Eq. 2 with the
parameters listed in Table 1.
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dilution was hdil ¼ 11 mcal for this concentrated poly-
electrolyte solution. hdil is identical to the hi observed at the
end of the titration shown in Fig. 2 A and is subtracted for the
evaluation of the thermodynamic parameters.
Even without invoking a speciﬁc binding model, Fig. 2
allows two quantitative conclusions. First, for the initial
injection phase, the heparan sulfate is much in excess over
the added TAT-PTD. The plateau region reveals that the
added TAT-PTD is bound completely to heparan sulfate.
The molar heat of binding for TAT-PTD is given by
DH0pephi=ni;p where ni,pep is the molar amount of peptide
added during each injection. The evaluation of the plateau
regions of three different peptide-into-HS titrations yields
DH0pep ¼ 4:66 1:0 kcal/mol. Secondly, as the titration
continues, the supply of free heparan sulfate becomes
exhausted and the titration peaks suddenly become smaller.
The midpoint of this transition is found at a TAT-PTD/HS
molar ratio of rpep/HS ¼ 6.2 6 0.2 (n ¼ 3). As a second
quantitative conclusion it follows that heparan sulfate binds
on the average r ¼ 6.2 6 0.2 TAT-PTD molecules. This
binding ratio leads essentially to charge neutralization as will
be discussed below.
The evaluation of the TAT-PTD/HS molar ratio rpep/HS
was based on a molecular weight of 14.2 kDa for HS.
Whereas the peptide concentration was determined with
amino acid analysis, the HS concentration was calculated
with a nominal molecular weight of 14.2 kD. HS is,
however, not homogeneous and the supplier speciﬁes
a molecular weight of 14.2 6 2 kDa. As the molecular
weight is uncertain by;15%, the error in rpep/HS is increased
by the same percentage. We therefore present a second
analysis which avoids the problem of polydispersity. The
sulfur content of the HS employed in the present studies was
determined as 6.44 wt %. The HS concentration of 12.0 mM
can thus be replaced by a sulfate concentration of 342.9 mM
which is independent of the chain length heterogeneity of
HS. The molar sulfate/peptide ratio at half-height of the
transition curve (Fig. 2 B) is rSO4 =pep ¼ 4:65: The HS chain
also contains ;1 carboxylate group per sulfate group
whereas the peptide carries a formal charge of zp ¼ 18.
The ratio of negative HS charges (SO41COO
) to positive
peptide charges at the midpoint of the titration curve is 2 3
4.65/8 ¼ 1.16. The midpoint of the transition is thus close to
the point of electric charge neutralization. It further follows
that the number of sulfate groups per HS molecule is rpep/HS
rSO4 =pep ¼ 28:86 4: The error of 15% is again determined
by the uncertainty in the molecular weight of heparan sulfate.
The quantitative results discussed above suggest that
heparan sulfate has n independent and equal binding sites for
TAT-PTD. It is then straightforward to describe the whole
binding isotherm by a simple model. If [M]total is the total
concentration of the macromolecule (e.g., heparan sulfate),
Lbound is the concentration of bound ligand (TAT-PTD
peptide), and [L] is the concentration of free ligand, then the
equilibrium can be described by
½Lbound
½Mtotal
¼ n K½L
11K½L : (1)
Even though Eq. 1 appears to be trivial, its derivation
involves a statistical averaging over all possible occupation
numbers (van Holde et al., 1998). The concentration of
bound ligand is given by
½Lbound ¼
1
2
1
K
1 ½Ltotal1 n½Mtotal
 
 1
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
K
1 ½Ltotal1 n½Mtotal
 2
4n½Mtotal3 ½Ltotal
s
: (2)
To connect Eq. 2 with the experimentally accessible heats of
reaction, hi, we denote with S an individual peptide binding
site. The total concentration of binding sites is [S]total ¼
n[M]total¼ nC0HS: The fraction of occupied binding sites after
i peptide injections is QS,b ¼ [Sb]/[S]total and can be de-
termined from the titration experiment according to
Q
ðiÞ
S;b ¼ +
i
k¼1
hk= +
‘
k¼1
hk: (3)
The concentration of bound peptide, [L]bound, is identical to
the concentration of occupied binding sites,
½Lbound ¼ ½Sb ¼ QS;b3 n½Mtotal ¼ QS;b3 n C0HS: (4)
[L]bound can thus be determined directly from the titration
experiment (Seelig, 1997; Wiseman et al., 1989). It is then
possible to evaluate n, DH0pep; and K0 according to Eq. 2 by
a three-parameter least-square ﬁt. The solid line in Fig. 2 is
the calculated binding isotherm. The reaction enthalpy at
288C is DHpep ¼ 4:656 1:0 kcal per mol of TAT-PTD and
the binding constant is K0 ¼ (5.7 6 2) 3 105 M1 (average
of three titrations). The number of peptides bound per
molecule heparan sulfate, averaged over all measurements, is
n ¼ 6.3 6 0.4 (cf. Table 1). The error is the standard
deviation of the thermodynamic titration. Taking into
account also the uncertainty in the molecular weight (15%)
the error is increased to n  6.3 6 1.3. This is in agreement
with the direct evaluation given above. In contrast,
evaluation of DH0pep and K0 is not affected by the poly-
dispersity of heparan sulfate.
HS-into-peptide titration
Next, Fig. 3 shows the inverse HS-into-peptide titration with
the peptide (78 mM) in the calorimeter cell and the heparan
sulfate solution (500 mM) added in 2-mL aliquots every
5 min. The binding reaction is again very fast and ﬁnished
within the response time of the instrument. As in the peptide-
into-HS titration discussed above, the heats of reaction are
initially exothermic, and drop to zero. However, in contrast
to the previous measurement, the hi values become slightly
endothermic before approaching the zero line again. The
cumulative heat of the exothermic reaction is ;440 mcal
HIV-1 TAT-PTD Binding to Heparan Sulfate 257
Biophysical Journal 86(1) 254–263
and that of the endothermic reaction ;130 mcal, i.e.,\7%
of the exothermic process. If the titration is performed with
more dilute peptide and heparan sulfate solutions, the
endothermic reaction can no longer be observed. We will
show below, with light scattering, that addition of heparan
sulfate to an excess of TAT-PTD probably leads to a cross-
linking of several HS molecules via TAT-PTD.
Fig. 3 reveals an almost constant heat of reaction of
DH0HS ¼ 30:76 1:4 kcal/mol for the ﬁrst few injections of
heparan sulfate. This is only possible if all added heparan
sulfate is completely bound to peptide. Since the binding of
a single peptide yields 4.7 kcal/mol, the peptide/HS
stoichiometry of binding is found to be npep/HS ¼ 30.8/
4.7¼ 6.6 which is in excellent agreement with the peptide-
into-HS titration described above.
We have evaluated the exothermic stage of the HS-into-
peptide titration again according to Eq. 2 and have
determined n, K, and DH0pep by a least-square ﬁt. We
observed no signiﬁcant difference between those titrations
which showed exclusively an exothermic phase and those
which also displayed a small endothermic phase. The
average DH0pep ¼ 4.5 6 0.6 kcal/mol (n ¼ 6), measured
with different concentrations of TAT-PTD and HS, is in
excellent agreement with the reaction enthalpy obtained in
the peptide-into-HS titration described before. The data are
summarized in Table 1.
We have used ITC to also study the binding of TAT-PTD
to another glucosaminoglycan, heparin, and to a galactosa-
minoglycan, chondroitin sulfate B. The ITC titration patterns
were virtually identical to those observed for heparan sulfate.
Likewise, the binding isotherms could again be described by
the multisite binding model of Eq. 1, and the resulting
parameters are included in Table 1. The binding constant, K0,
and the reaction enthalpy, DH0pep; of a single site are similar
to the results obtained for heparan sulfate. Indeed, the only
major difference found between the three glycosaminogly-
cans is the number of binding sites for TAT-PTD which is
n; 6.5 for heparan sulfate,;4.2 for heparin, and;14.8 for
chondroitin sulfate B. Since the three species have a different
molecular weight, a more meaningful comparison is the
binding capacity per 1 kDa which is ;0.46 for heparan
sulfate, ;0.53 for chondroitin sulfate B, and ;0.69 for
heparin. Hence heparin has a 30–50% higher binding
capacity for TAT-PTD than heparan sulfate which may be
traced back to its higher extent of sulfatation (cf. below).
Light-scattering and circular dichroism
TAT-PTD has a small intrinsic ﬂuorescence due to its single
tyrosine residue. When TAT-PTD was titrated into pure
buffer, a small linear increase in the ﬂuorescence was
observed, as shown in Fig. 4 A. Next TAT-PTD (393 mM)
was titrated into heparan sulfate (6 mM). Fig. 4 A displays the
TABLE 1 Thermodynamic parameters for binding of HIV-1 TAT-PTD to different glycosaminoglycans
Temp (8C)
Number of
binding sites* K0 (M
1)
DH0pep (kcal/mol
peptide)
DG0pep (kcal/mol
peptide)
TDS0 (kcal/mol
peptide)
Number of
measurementsy
Heparan sulfate (MW 14.2 6 2 kDa)
18 6.5 8.0 3 105 5.6 7.8 2.2 1
28 7.0 6 0.3 (6.0 6 0.6) 3 105 4.5 6 0.6 7.9 6 0.1 3.4 6 0.6 6z
28 6.3 6 0.4 (5.7 6 2) 3 105 4.6 6 1.0 7.9 6 0.3 3.3 6 1 3§
38 7.1 5.0 3 105 2.9 8.1 5.2 1
Chondroitin sulfate B (MW 28 kDa)
28 14.8 6 1.5 (2.5 6 0.5) 3 105 3.2 6 0.4 7.4 6 0.2 4.2 6 0.5 6
Heparin (MW 6 6 1 kDa)
28 4.2 6 0.4 (6.0 6 0.8) 3 105 5.1 6 0.7 7.9 6 0.1 2.7 6 0.7 7
*Mean 6 SD of the calorimetric measurement. If the dispersion of the molecular weight is included, the total error is ;20%.
yAt different peptide and glycosaminoglycan concentrations.
zHS-into-TAT-PTD titration.
§TAT-PTD-into-HS titration.
FIGURE 3 Isothermal titration calorimetry. Titration of heparan sulfate
into TAT-PTD. (A) Heat ﬂow. The peptide concentration in the reaction cell
is 78 mM. Each peak corresponds to the injection of 2 mL (every 5 min) of
heparan sulfate at a concentration of 500 mM. Buffer is 10 mM Tris and 100
mM NaCl at pH 7.4. Temperature is 288C. (B) Heats of reaction hi
(integrated from the heat ﬂow in A) as a function of the molar ratio of
heparan sulfate/TAT-PTD. Unﬁlled diamonds represent experimental data.
The solid line is the least-square ﬁt to these data using the binding model
described by Eq. 2 with the parameters listed in Table 1.
258 Ziegler and Seelig
Biophysical Journal 86(1) 254–263
difference spectrum after subtraction of pure TAT-PTD.
After an initially ﬂat baseline during the ﬁrst few injections,
the difference spectrum shows a weak scattering intensity
with a maximum at a peptide/HS molar ratio of npep/HS¼ 6.4.
A much more dramatic effect is observed for the inverse
HS-into-TAT-PTD titration (Fig. 4 B). HS itself is non-
ﬂuorescent, leading to a ﬂat baseline when HS is titrated into
buffer only. Next HS (160 mM) was titrated into TAT-PTD
(30 mM), both in the same buffer (10 mM Tris and 100 mM
NaCl, at pH 7.4, 288C). The ﬂuorescence scattering was
much more pronounced (see below) and the scattering curve
showed a maximum at nHS/pep ¼ 0.16 6 0.02 (n ¼ 4) which
corresponds to a peptide/HS ratio of npep/HS ¼ 6.3.
Despite the fact that the maximum of the two scattering
curves is characterized by almost the same npep/HS value
(which also agrees with the stoichiometry determined from
ITC) the peptide-into-HS titration produces a much higher
turbidity than the inverse titration. Indeed, when comparing
Fig. 4 A with Fig. 4 B it should be realized that the
photomultiplier was in the high sensitivity detection mode in
Fig. 4 A but in low sensitivity in Fig. 4 B. Thus the scattering
intensity is;1000-fold less in Fig. 4 A compared to Fig. 4 B.
This is also obvious when inspecting the two solutions by
eye. At the scattering maximum the solution corresponding
to Fig. 4 A is only weakly opalescent. In contrast, solution of
Fig. 4 B is milky turbid.
We explain these different results for the two titrations by
two structurally different, but thermodynamically almost
identical complexes. In the peptide-into-HS titration, HS is
much in excess over the added peptide. During the initial
stage of the titration individual TAT-PTD molecules are
mainly bound to one and only one HS molecule. In the
inverse titration, TAT-PTD is in excess over HS. The
addition of HS could lead to a cross-linking of several HS
molecules via TAT-PTD. At the scattering maximum, cross-
linking is observed for both titrations but the complexes are
distinctly larger for the HS-into-peptide titration than in the
inverse case. In addition, aggregation of neutral complexes
could also contribute to the scattering curves. It should also
be noted that upon further addition of either reactant beyond
the stoichiometric maximum, the complexes/aggregates are
brought back into solution.
Circular dichroism spectroscopy reveals a random coil
structure for TAT-PTD in buffer. Addition of heparan sulfate
produced no conformational change at all molar ratios tested
(spectra not shown). However, the signal amplitude de-
creased with increasing heparan sulfate concentration as a
consequence of aggregation and light scattering.
DISCUSSION
Cell-penetrating peptides are polybasic in nature and appear
to penetrate the plasma membrane via a temperature-in-
dependent, nonendocytotic pathway. Recent reports demon-
strate an intriguing role for heparan sulfate proteoglycans as
a plasma membrane carrier and cellular entry mechanism
(for a review see Belting, 2003). Here we address the
question of the thermodynamic forces governing such an
interaction.
TAT-PTD-heparan sulfate binding equilibrium
This study is the ﬁrst thermodynamic characterization of the
interaction of a TAT-PTD peptide with heparan sulfate.
Heparan sulfate is extracellular in distribution and has been
identiﬁed in many different tissues. It is localized in the
basement membrane and on the cell surface and typical
concentrations of heparan sulfate proteoglycans are in the
range of 105–106 molecules/cell as measured in various cell
culture systems. The interaction of TAT and TAT-derived
basic peptides with the ubiquitous heparan sulfate is thus of
general biological relevance (Sandgren et al., 2002). Earlier
TAT binding studies have used mainly heparin, a compound
found in intracellular granules of mast cells, which is more
easily available. Heparan sulfate and heparin have the same
basic structure consisting of repeating disaccharides IdoA/
GlcUA and GlcNAc (Fig. 1). A distinction between the two
molecules can be made via the extent of sulfatation that is
approximately two sulfate residues per disaccharide unit in
heparin compared to approximately one sulfate in heparan
sulfate (Rusnati et al., 1997). However, heparin is an in-
tracellular component predominantly localized in mast cells
and is thus not immediately accessible to TAT.
Isothermal titration calorimetry shows that the TAT-PTD
peptide binds rapidly and tightly to heparan sulfate, heparin,
FIGURE 4 Static right-angle light scattering. (A) Titration of TAT-PTD
into heparan sulfate (HS). The HS concentration in the optical cuvette (Vcell
¼ 2.8 mL) is 6 mM. Each peak corresponds to the injection of 20 mL (every
minute) of TAT-PTD at a concentration of 393 mM. (}) TAT-PTD into pure
buffer. (¤)TAT-PTD injected into the HS solution (difference spectrum
after baseline correction with TAT-PTD-into-buffer injection). (B) Titration
of heparan sulfate into TAT-PTD. The TAT-PTD concentration in the
optical cuvette is 26 mM (2.8074 mL). (¤) Each peak corresponds to the
injection of 4 mL (every minute) of heparan sulfate at a concentration of 167
mM. (}) Heparan sulfate is injected into buffer without peptide. Buffer in all
experiments is 10 mM Tris and 100 mM NaCl. Temperature is 288C.
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and chondroitin sulfate B with similar intrinsic binding
constants in the range of K0 ¼ 33 105 M1 to 63 105 M1
at 288C. The measurements also demonstrate that the three
glycosaminoglycans have multiple independent binding sites
for TAT-PTD. The thermodynamic parameters of the
binding sites are very similar and it can be concluded that
the TAT-PTD recognition sites on the three glycosamino-
glycans must have similar structure and charge. In contrast,
the binding capacity, i.e., the number of binding sites per unit
molecular weight, varies for the three molecules and
increases in the order of heparan sulfate (0.46 binding sites
per 1 kDa), chondroitin sulfate B (0.53), and heparin (0.69),
and follows roughly the extent of sulfatation.
The implication of these binding parameters for biological
processes requires further investigations. For the inhibition
of TAT transduction, chondroitin sulfate B could not com-
pete with heparin (Rusnati et al., 1997) whereas for the
inhibition of TAT transactivation, chondroitin sulfate B was
as effective as heparin (Tyagi et al., 2001). For the
glycosaminoglycan-binding protein IGFBP, heparin and
chondroitin sulfate B had similar binding afﬁnities, but the
binding afﬁnity decreased in the order of chondroitin sulfate
B[ chondroitin sulfate A[ chondroitin sulfate C (Fowlkes
and Serra, 1996).
The calorimetric titration experiment provides the reaction
enthalpy, DH0, and the binding constant, K0, of the
elementary binding step. Fig. 5 displays the temperature
dependence of the two parameters for heparan sulfate. The
binding reaction is exothermic at all temperatures studied
and the reaction enthalpy is the major driving force for the
reaction at low temperatures. DH0pep becomes less negative
with increasing temperature. The slope of the straight line in
Fig. 5 A yields the molar heat capacity which is large and
positive with DC0p ¼ 1135 cal/mol K (referred to TAT-
PTD). This result is in contrast to hydrophobic reactions
where DC0p is negative; however, it is in agreement with the
characteristic signature of ionization/charge neutralization
reactions. Ionization reactions have substantial negative
values of DS0 and DC0p. The values of DS
0; 20 cal/mol K
and DC0p; 40 cal/mol K are typical of a dissociation to
singly charged ions in aqueous solution at room temperature
(Lewis et al., 1961). Conversely, charge neutralization is
accompanied by a positive DC0p and may proceed even if
DH0 is substantially endothermic because of the positive
DS0. Inspection of Table 1 indeed demonstrates that the
interaction of the TAT-peptide with heparan sulfate is ac-
companied by considerable increase in entropy; at high
temperatures ([388C) the TDS0-term even exceeds the
absolute value of the DH0-term. As a general conclusion it
follows that the binding of TAT-PTD to heparan sulfate is
dominated by electrostatic interactions.
The binding constant K0 decreases with increasing
temperature as anticipated for an exothermic reaction (Fig.
5 B). The solid line in Fig. 5 B represents the predicted
temperature dependence of K0 calculated with the temper-
ature-dependent DH0 taken from Fig. 5 A.
For a macromolecule with n independent binding sites the
measurable binding constants of the individual binding steps
vary with the degree of saturation for statistical reasons
according to (Tanford, 1961; van Holde et al., 1998)
Ki ¼ n1 1 i
i
K0: (5)
The ﬁrst peptide binds with the binding constant K1 ¼ nK0,
the last with Kn ¼ K0/n. For heparan sulfate with n ¼ 7
binding sites for TAT-PTD, the ratio K1/Kn ¼ n2 is 49.
Hence the initial binding step has an ;503 larger binding
constant than that measured near the saturation limit. This
large difference between the initial binding and the binding
near the saturation limit could eventually be misinterpreted
in terms of two types of binding sites with high and low
afﬁnity, respectively. Under in vivo conditions, HS is
probably much in excess over TAT-PTD and the initial
binding constant K1 ¼ 7 K0  4.2 3 106 M1 applies.
Thermodynamics provides only limited insight into the
molecular details of the complexes formed. The light-
scattering data reveal two different structures depending on
how the equivalence point of the titration is reached. If HS is
initially in excess, the few TAT-PTDs are distributed among
the many HS molecules and the solution remains optically
clear. The HS molecules are not saturated with TAT-PTD.
On the other hand, if TAT-PTD is in excess over HS, even
the ﬁrst addition of HS generates some turbidity which
increases linearly with the amount of added HS. The HS
molecules are immediately saturated with TAT-PTD even on
the ﬁrst injection of HS. We suggest that both cross-linking
and aggregation contribute to the observed turbidity. Both
processes are, however, not accompanied by signiﬁcant heat
FIGURE 5 Temperature dependence of the reaction enthalpy, DH0, and
the binding constant, K0, for TAT-PTD binding to heparan sulfate. (A)
DH0pep versus temperature. (B) K0 versus temperature. (}) Experimental
values. Solid line in A, linear regression analysis yielding DH0pep (kcal/mol)
¼ 0.135 T(C8) 8.108. Solid line in B, predicted temperature dependence of
K0 using the above regression formula for DH
0(T).
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changes as anticipated for amorphous precipitates or col-
loidal suspensions.
Comparison with related binding studies
To the best of our knowledge, no other quantitative data on
the heparan sulfate-TAT (or TAT-PTD) equilibrium are
available to date. Earlier studies have focused essentially on
heparin as a ligand since it is more easily available. It was
demonstrated that heparin binds speciﬁcally to recombinant
HIV-1 TAT produced as glutathione S-transferase (GST)
fusion protein and immobilized on glutathione-agarose
beads (Rusnati et al., 1998). However, replacing the six
arginins in the TAT domain (residues 49–57) by alanins
reduced the binding constant only by a factor 3. This would
argue against a strong electrostatic contribution (Rusnati
et al., 1998). Using heparins of different chain length it was
further found that the GST-TAT:heparin stoichiometry is
between 6:1 and 3:1 when the heparin concentration is low
and the chain length is 22 monomer units or more. For short
chains and high heparin concentrations a 1:1 stoichiometry
was observed. In addition, a low and a high afﬁnity binding
site were postulated based on Scatchard plots (Rusnati et al.,
1999). These data partially agree with our results but cannot
be made completely consistent. For a critical evaluation of
the discrepancies it should be realized that ITC is a simple
and straightforward physical-chemical experiment which is
ﬁnished in 60–90 min and delivers the whole binding
isotherm in a single experiment. In addition our experiments
were performed with the short TAT-PTD peptide comprising
just 11 amino acids. In contrast, the glutathione-agarose
assay is a lengthy biochemical procedure where the TAT
peptide is immobilized and the entire peptide (86 residues) is
coupled to a larger protein.
Biological consequences of complex formation
with heparan sulfate
Heparan sulfate at the cell surface is not freely diffusible but
is part of larger HSPG glycoproteins (such as agrin,
syndecan, etc.) which are transmembranous. These HSPGs
might act as co-receptors for various functions (Carey,
1997). In the absence of ligands, HSPGs are distributed at
random on the cell surface whereas in the presence of
speciﬁc ligands HSPGs may aggregate and co-localize with
other components of the cytoplasmic machinery (Martinho
et al., 1996). The TAT-PTD peptide investigated here has
a sufﬁciently strong binding afﬁnity to HS to induce
aggregation by cross-linking HS molecules located on
neighboring HSPGs. After cross-linking additional mecha-
nisms of uptake could be activated (Carey, 1997).
The indiscriminate and almost equally tight binding of
TAT-PTD to different glycosaminoglycans can explain both
activating and inhibitory mechanisms of TAT. If the cell
surface carries only a few selected proteoglycans, TAT-PTD
binding is limited to a few receptor molecules. In contrast, if
the cell surface offers a broad range of glycosaminoglycans,
TAT-PTD binding is nonselective and will follow statistical
principles. Addition of external HS could also produce
regulatory effects. Added at stoichiometric amounts, a neutral
TAT-PTD/heparan sulfate complex can be formed which, in
turn, can be adsorbed to the membrane surface and activate
consecutive reaction steps. Added in excess, heparan sulfate
brings the HS/TAT-PTD complex back into solution and the
peptide is removed from further interactions.
By analogy, we expect a similar mechanism for heparin
which may explain both stimulatory and inhibitory effects of
heparin/TAT interaction observed in cell proliferation. The
full length HIV-TAT protein has been found to be an angio-
genic growth factor. TAT induces endothelial cell prolifera-
tion after the cells have been stimulated by cytokines
(Barillari et al., 1992). Low doses of heparin enhanced this
response to TAT and high doses of heparin inhibited this
proliferative response (Albini et al., 1996). At low heparin
concentrations, the added heparin will be completely com-
plexed with TAT. The electrically neutral complex might
then interact with outer cell membrane components (HSPGs)
or translocate diffusively through the cell membrane. As
more heparin is added, the neutral, TAT-saturated complex
will be dissolved in favor of heparin/TAT complexes with an
excess negative charge. At this stage the complex is repelled
from the membrane surface and heparin acts inhibitorily.
In summary, isothermal titration calorimetry has provided
detailed quantitative insight into the interaction between the
cationic TAT-PTD peptide and anionic glycosaminoglycans.
The anionic macromolecules have several independent
binding sites for TAT-PTD and the density of binding sites
is roughly correlated with the extent of sulfatation. The
dissociation constant of the TAT-PTD complex is KD ; 1
mM and is approximately three orders-of-magnitude smaller
than that observed for negatively charged lipid membranes
(Ziegler et al., 2003). Binding of TAT-PTD (and, in turn,
TAT) to glycosaminoglycans on the cell surface is hence
distinctly more probable than binding to the lipid bilayer.
The tight interaction of TAT-PTD with glycosaminoglycans
and the formation of different types of charged or neutral
TAT-PTD glycosaminoglycan complexes provides a solid
physical-chemical foundation for the involvement of pro-
teoglycans in TAT translocation across the cell membrane.
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